公开(公告)号：US20240132499A1

公开(公告)日：2024-04-25

申请号：US18476249

申请日：2023-09-27

申请人： FORMA Therapeutics, Inc.

发明人： Alex J. Buckmelter ,  Justin Andrew Caravella ,  Hongbin Li ,  Matthew W. Martin ,  Steven Mischke ,  David James Richard ,  Angela V. West

IPC分类号： C07D471/18 ,  C07D403/12 ,  C07D471/08 ,  C07D487/08 ,  C07D487/18 ,  C07D491/107

CPC分类号： C07D471/18 ,  C07D403/12 ,  C07D471/08 ,  C07D487/08 ,  C07D487/18 ,  C07D491/107

摘要： The disclosure relates to USP30 Inhibitor Compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.

公开(公告)号：US20240131011A1

公开(公告)日：2024-04-25

申请号：US18125932

申请日：2023-03-24

申请人： FORMA Therapeutics, Inc.

发明人： George P. Luke ,  Suresh Babu

IPC分类号： A61K31/436 ,  A61K9/00 ,  A61K9/20

CPC分类号： A61K31/436 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054

摘要： The present disclosure provides crystalline solid forms, spray-dried dispersions and pharmaceutical compositions, including solid oral dosage forms, of (S)-1-(5-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7-sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-3-hydroxy-2-phenylpropan-1-one (“Compound 1”), and preparation methods thereof.

公开(公告)号：US11963956B2

公开(公告)日：2024-04-23

申请号：US17700027

申请日：2022-03-21

申请人： FORMA Therapeutics, Inc.

发明人： Patrick F. Kelly ,  Susan Ashwell ,  Blythe Thomson ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Wei Lu

IPC分类号： A61K31/4709 ,  A61P35/00

CPC分类号： A61K31/4709 ,  A61P35/00

摘要： Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

公开(公告)号：US20240033261A1

公开(公告)日：2024-02-01

申请号：US18215727

申请日：2023-06-28

申请人： FORMA Therapeutics, Inc.

发明人： George P. Luke ,  Pratik Sheth

IPC分类号： A61K31/4709 ,  A61K9/00 ,  A61K47/12 ,  A61K47/38

CPC分类号： A61K31/4709 ,  A61K9/0053 ,  A61K47/12 ,  A61K47/38

摘要： The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.

公开(公告)号：US11795168B2

公开(公告)日：2023-10-24

申请号：US17482717

申请日：2021-09-23

申请人： FORMA Therapeutics, Inc.

发明人： George Luke ,  Suresh Babu

IPC分类号： C07D471/04 ,  A61K9/48 ,  A61K9/16

CPC分类号： C07D471/04 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866

摘要： The present disclosure is directed to solid and salt forms of inhibitors of the CBP/p300 family of bromodomains made up of salts and crystalline forms of Formula (I). The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds.

公开(公告)号：US20230061891A1

公开(公告)日：2023-03-02

申请号：US17383610

申请日：2021-07-23

申请人： FORMA Therapeutics, Inc.

发明人： Kenneth W. Bair ,  Torsten Herbertz ,  Goss S. Kauffman ,  Katherine J. Kayser-Bricker ,  George P. Luke ,  Matthew W. Martin ,  David S. Millan ,  Shawn E.R. Schiller ,  Adam C. Talbot

IPC分类号： C07D401/04 ,  C07D401/14 ,  A61K31/4709 ,  A61K45/06 ,  A61K31/47 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  C07D405/14 ,  C07D413/14 ,  C07D215/20 ,  C07D215/48 ,  C07D409/14 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D473/28 ,  C07D487/04 ,  A61K31/517 ,  A61K31/519 ,  A61K31/496 ,  A61K31/501 ,  A61K31/52 ,  C07D401/12 ,  C07D405/04 ,  C07D417/10

摘要： The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.

公开(公告)号：US11498913B2

公开(公告)日：2022-11-15

申请号：US17101018

申请日：2020-11-23

申请人： FORMA Therapeutics, Inc.

发明人： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, Jr. ,  Justin Andrew Caravella ,  Wei Lu

IPC分类号： C07D401/12 ,  C07D401/14 ,  C07D471/04 ,  A61P35/00 ,  A61K31/47

摘要： The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

公开(公告)号：US11299484B2

公开(公告)日：2022-04-12

申请号：US17021759

申请日：2020-09-15

申请人： FORMA Therapeutics, Inc.

发明人： Matthew W. Martin ,  Mary-Margaret Zablocki ,  Scot Mente ,  Christopher Dinsmore ,  Zhongguo Wang ,  Xiaozhang Zheng

IPC分类号： C07D405/14 ,  C07D221/20 ,  C07D409/14 ,  C07D413/14 ,  C07D405/06

摘要： The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.

公开(公告)号：US20220088005A1

公开(公告)日：2022-03-24

申请号：US17482720

申请日：2021-09-23

申请人： FORMA Therapeutics, Inc.

发明人： Sylvie GUICHARD ,  Maureen CALIGIURI ,  Anna ERICSSON ,  Qunli XU ,  Hesham MOHAMED

IPC分类号： A61K31/4745 ,  A61P35/00

摘要： Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed. In some methods, the AR-positive forms of cancer may be breast cancer, including triple negative forms, hormone receptor positive forms, and HER2-positive forms. In other methods, the AR-positive forms of cancer may be prostate cancer, including metastatic castration resistant prostate cancer. In some embodiments, methods of treating prostate cancer comprise the step of administering to a patient in need thereof the compound (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220073525A1

公开(公告)日：2022-03-10

申请号：US17417805

申请日：2019-12-27

申请人： FORMA Therapeutics, Inc.

发明人： Alexandre Joseph Buckmelter ,  Justin Andrew Caravella ,  Jian Lin ,  Edward L. Fritzen

IPC分类号： C07D487/04

摘要： This disclosure relates to modulating ubiquitin specific protease 1 (USP1) and provides novel chemical compounds useful as inhibitors of USP1, as well as various uses of these compounds. USP1 inhibiting compounds are useful in the treatment of diseases and disorders associated with USP1, such as cancer.